Johnson & Johnson Stock (JNJ) Dips Amid U.S. Manufacturing Expansion Plans
Johnson & Johnson shares declined despite announcing a $2 billion investment in North Carolina to expand U.S. manufacturing capabilities. The move comes as the healthcare giant seeks to mitigate potential impacts from proposed TRUMP administration tariffs on pharmaceutical imports, which could eventually reach 250%.
The new 160,000-square-foot facility at Fujifilm Biotechnologies' Holly Springs site signals J&J's commitment to domestic production of advanced medicines. This follows a March pledge to increase U.S. investments by 25% to $55 billion over four years, potentially boosting local sales while navigating trade policy uncertainties.